Patent · US Active

Interferon alpha and interferon kappa fusion protein

US7888475B2 · kind B2 · utility

4Cited by

1References

2Claims

0Family size

Inventors

Hal S. Padgett · Vacaville, US
Fakhrieh S. Vojdani · Davis, US
Andrew A. Vaewhongs · Vacaville, US

Key dates

Filing date	Sep 15, 2009
Grant date	Feb 15, 2011
Priority date	—
Expiry date	Sep 15, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/24011
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Herein is described a system to combat poxvirus infection wherein antagonists are developed that bind the soluble cytokine receptor but have no significant biological activity in the host, effectively blocking the virus-mediated suppressor of interferon function, thereby permitting the host's own cytokines to stimulate an antiviral response. Alternatively, interferon molecules can be developed that retain biological activity on their native receptors but fail to bind the viral cytokine binding protein, thereby circumventing this virus immune modulation mechanism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.